Viral Reactivation, IgG, and Chronic Illness %Tri-Health Naturopathic Integrate Wellness Biohacking Regenerative Beauty

Sep 29

2026

What elevated antibodies actually mean — a dual-audience briefing for patients and clinicians

Dr. Jason Granzotto ND · Naturopathic Doctor · Founder, Tri-Health Wellness Centre
Educational review for the public and clinicians · September 2026

The short version

Most adults already carry lifelong latent viruses such as Epstein–Barr virus (EBV), cytomegalovirus (CMV), herpes simplex, varicella-zoster, and HHV-6. A positive IgG test usually means past exposure — not that a virus is currently attacking the body.

Reactivation is different. It means a quiet virus has started replicating again. That can happen when cellular immunity is strained, when inflammation is high, after another infection (including SARS-CoV-2), with aging, stress, poor sleep, or immunosuppressive drugs.

Elevated virus-specific IgG, especially antibodies to EBV early antigen (EA-D), rising titers, IgA, or detectable viral DNA/RNA, can be a clue — but IgG alone is not a diagnosis. Total (polyclonal) IgG elevation is a separate finding that usually reflects chronic immune activation, liver disease, autoimmunity, or infection — not a single virus.

The evidence is strongest that EBV is a causal driver of multiple sclerosis. For long COVID, ME/CFS, autoimmunity, and aging-related illness, reactivation is a serious and biologically plausible contributor, but it is often both a cause and a consequence of immune disruption. Honest interpretation sits between two errors: dismissing all of this as “just old antibodies,” and treating every high IgG as proof of an active, treatable infection.

Part I — For patients and the public

The viruses that never quite leave

A first meeting with a herpesvirus is usually obvious: mono from EBV, a cold sore from HSV-1, chickenpox from varicella-zoster, or a CMV infection that may have been silent. After that first encounter, these viruses do not pack up and leave. They settle into specific cells — B cells for EBV, myeloid and endothelial cells for CMV, sensory nerve ganglia for HSV and VZV — and go quiet. That quiet state is latency.

Latency is not the same as “cured,” and it is not the same as “active infection.” In a healthy person the immune system keeps the virus suppressed most of the time. Tiny, usually unnoticed bursts of activity can still occur. The problem starts when those bursts become larger, more frequent, or more inflammatory — what clinicians call reactivation.

You already live with this biology. Roughly nine in ten adults worldwide have met EBV. A large share have met CMV, HSV, and VZV. Finding “positive IgG” on a lab report is, for most people, as expected as finding a scar from an old injury. The scar proves something happened. It does not prove the wound is open.

What IgG is — and what it is not

Antibodies come in classes. IgM is the early alarm. IgG is the long-term memory file. After many infections, IgG can stay detectable for years or for life. That is why a single positive virus-specific IgG result almost never answers the question patients actually ask: “Is this virus making me sick right now?”

There are two different “high IgG” findings that get mixed together on lab printouts, and they do not mean the same thing.

Virus-specific IgG. Example: EBV VCA IgG or CMV IgG. This says your immune system has seen that virus. High titer can mean more antigenic stimulation over time, including past reactivation, but it can also simply mean a strong memory response.
Total (polyclonal) IgG. This is the whole antibody pool. When it is high, the immune system is broadly activated. Common drivers are chronic inflammation, autoimmune disease, liver disease, chronic infection, and — less often — rare immune disorders. It is a smoke detector, not a nameplate on the fire.

A useful everyday analogy: IgG is the filing cabinet. A thick file on EBV means the cabinet has a lot of paper about that virus. It does not tell you whether the virus is currently in the building. To guess that, you need the right combination of files (early-antigen antibodies, IgA, changing titers) plus, when it matters, a direct look for viral genetic material.

When “old” viruses wake up

Reactivation is not rare in hospitals. In critically ill COVID-19 cohorts, herpesvirus reactivation has been reported in a large majority of patients, with EBV often the most common. Concurrent reactivation of more than one virus is frequent and tracks with worse outcomes. That is the extreme end of the spectrum.

Outside the ICU, quieter reactivation happens with:

A new infection that floods the system with inflammation — SARS-CoV-2 is the best-studied recent example.
Physiological stress: major illness, surgery, sleep loss, severe psychological stress.
Aging of the immune system, especially in people who also carry CMV.
Medications that suppress T-cell surveillance: high-dose steroids, some biologics, chemotherapy, transplant drugs.
Hormonal shifts, nutrient depletion that impairs lymphocyte function, and poorly controlled metabolic or gut inflammation.

A 2026 Nature analysis of more than 1,100 hospitalized COVID-19 patients found RNA from multiple latent viruses, with EBV appearing early and CMV and HSV-1 later. Importantly, reactivation in that study was tied more closely to inflammation than to immunosuppressive drugs. The old textbook line — “only immunocompromised people reactivate viruses” — is incomplete. Immunocompetent people reactivate them too when the inflammatory and cellular-immune environment changes.

Is this a sign of “weakened immunity”?

Sometimes yes. Often the more accurate phrase is dysregulated immunity — a system that is busy, misdirected, exhausted in some compartments, and overactive in others.

Three patterns show up again and again:

True surveillance failure. Not enough effective T-cell control. Classic examples are transplant recipients, untreated advanced HIV, and some primary immunodeficiencies. This is the setting in which CMV, EBV, and VZV can cause overt, tissue-invasive disease.
Occupied immunity. CMV in particular drives “memory inflation”: a growing share of T cells is assigned to watching CMV for life. That crowded repertoire is one reason aging immune systems respond less well to new threats. The system is not empty. It is overbooked.
Inflammatory ignition. High IL-6, TNF, and interferon-pathway activity can itself pull latent viruses out of hiding. Here reactivation is not proof that immunity has collapsed. It can be proof that the inflammatory thermostat is stuck high.

That distinction matters for patients. “Your immunity is weak” can sound like a moral or lifestyle verdict. The biology is more specific: certain T-cell jobs are underperforming, certain inflammatory loops are overperforming, and latent viruses exploit the gap. Those are measurable, and some of them are modifiable.

How this shows up in chronic illness

No serious researcher now claims that every case of fatigue, autoimmunity, or brain fog is “just EBV.” The better claim, supported by a growing stack of studies, is that latent-virus biology is one of the mechanisms that can lock a person into a chronic inflammatory or post-infectious state.

Multiple sclerosis — the strongest causal story

In 2022, a Science paper following more than 10 million U.S. military personnel found that MS risk rose 32-fold after EBV infection and did not rise after CMV, a similarly transmitted virus. Almost no MS cases occurred in people who remained EBV-negative. Nerve-injury markers rose only after EBV seroconversion. That is as close as human epidemiology usually gets to “this virus is required for this disease.” It still does not mean everyone with EBV gets MS — genetics, vitamin D, smoking, and other hits matter — but it ended the idea that EBV is a bystander in MS.

Long COVID

Several independent groups have found serologic fingerprints of recent EBV activity — especially EA-D IgG — more often in people with persistent fatigue and neurologic symptoms after COVID-19 than in recovered controls. One early study reported EBV-reactivation markers in about two-thirds of people with long-COVID symptoms versus about 10% of controls. Later work has been more mixed: some large multi-omics studies link persistent symptoms more tightly to other chronic viruses (Anelloviridae) than to EBV itself, while still documenting frequent herpesvirus reactivation during the acute illness. The fairest summary in 2026 is that SARS-CoV-2 can wake latent viruses; those reactivations track with inflammation and some long-term symptoms; they are not the only explanation for long COVID.

ME/CFS and post-infectious fatigue

ME/CFS research has circled herpesviruses for decades. Newer work is more precise than “high EBV IgG.” Studies measuring antibodies to viral lytic enzymes (dUTPases) find that many people with ME/CFS carry signatures of concurrent EBV, HHV-6, and VZV activity, and that those antibody levels correlate with fatigue severity. Sputum studies have found higher EBV copy numbers in ME/CFS than in controls. Meta-analyses do not crown a single virus as the cause. They do support a model in which several persistent viruses, sometimes in an abortive or incomplete replication state, keep the innate immune system on a low boil.

Autoimmune disease

EBV is repeatedly associated with lupus, rheumatoid arthritis, Sjögren’s, and inflammatory bowel disease. Mechanisms include molecular mimicry (viral proteins that look like human proteins), infected B-cell survival, and bystander inflammation. High anti-EBV titers often travel with higher disease activity, but again: titer is not the same as proof that killing the virus would extinguish the autoimmune disease. It is a reason to take the viral-immune axis seriously when someone has both autoimmunity and a post-viral picture.

Aging, vessels, and “inflammaging”

CMV is the specialist here. Lifelong CMV surveillance remakes the T-cell compartment. Combined EBV-plus-CMV seropositivity with high antibody titers has been linked to higher CRP and IL-6 in older adults. That is one proposed engine of the low-grade inflammation that accompanies vascular disease, frailty, and poorer vaccine responses.

What a thoughtful workup looks like

If you feel unwell and a lab says “EBV IgG positive,” that sentence by itself should not change your life. A more useful conversation asks:

Is this a full EBV panel (VCA IgM/IgG, EBNA IgG, EA-D IgG) or a single checkbox?
Are titers high, rising, or accompanied by IgA?
Is there PCR evidence of circulating or mucosal viral DNA when the clinical picture is severe or atypical?
Is total IgG high, and if so, is that polyclonal? Are liver enzymes, CRP, autoimmune markers, and blood counts also off?
What else could be driving immune strain — sleep, iron, B12, thyroid, gut dysbiosis, food-triggered inflammation, metabolic disease, mood and trauma load, medications?

Treatment, when it is considered, should target the terrain as much as the virus: restore sleep and metabolic stability, reduce unnecessary inflammatory load, correct deficiencies that impair lymphocyte function, and only then discuss targeted antivirals or immune therapies with a clinician who knows both the evidence and the limits of the evidence. There is no responsible over-the-counter “EBV cleanse.”

Part II — For clinicians

Definitions that keep interpretation honest

Latency. Restricted viral gene expression; genome maintained as episome (herpesviruses) or integrated/cccDNA reservoir (HBV). Immune control is primarily CD8+ and NK-cell mediated, with CD4 help.
Lytic reactivation. Full or partial return of the replicative program. Complete lytic cycles produce virions; abortive lytic programs can still express inflammatory and immunomodulatory proteins (e.g., herpesvirus dUTPases) without a large viremia.
Serologic memory vs antigenic re-challenge. Stable VCA IgG + EBNA-1 IgG without EA-D is past infection. EA-D IgG, VCA IgA, four-fold titer rise, or antibodies to replication enzymes are closer to recent or ongoing antigenic exposure. Even those are imperfect.
DNAemia is not synonymous with disease. Low-copy EBV DNA can appear in healthy shedders. Tissue-restricted reactivation is systematically under-detected by blood PCR. Absence of viremia does not exclude a pathogenic mucosal or lymphoid reservoir.

How to read an EBV panel

A three-marker panel (VCA IgM, VCA IgG, EBNA-1 IgG) distinguishes primary infection from past infection in most immunocompetent adults. It is a weak tool for reactivation. Adding EA-D IgG, VCA IgA, avidity, and, when indicated, quantitative PCR improves resolution. CDC language is explicit: high VCA IgG titers persist and are not diagnostic of recent infection by themselves.

Pattern	Typical serology	Usual meaning	Caveats
Never infected	VCA IgG−, EBNA−, EA−	No prior EBV	Rare in adults; confirm if clinically important
Acute primary	VCA IgM+, VCA IgG+/−, EBNA−	Infectious mononucleosis window	Heterophile false negatives in children; IgM can be nonspecific
Past, latent	VCA IgG+, EBNA+, EA-D−, IgM−	Expected adult pattern	Does not exclude tissue-restricted activity
Suggestive reactivation	EA-D IgG+, often high VCA IgG, IgA+/−, IgM variable	Recent lytic-cycle antigen exposure	~20% of healthy people keep EA-D for years; pair with clinical context
Chronic active EBV (rare)	Very high VCA/EA titers; PCR ≥10⁴ IU/mL whole blood; infected T/NK cells	Defined rare disease, not “high IgG fatigue”	Do not apply CAEBV criteria to ordinary post-viral fatigue

IgG avidity can separate recent primary infection (low avidity) from past infection or reactivation (high avidity). Antibodies to EBV DNase and DNA polymerase historically clustered with extreme VCA titers and, in a small 1988 series, with later lymphoma — a reminder that extreme serologic profiles deserve hematologic follow-up, not herbal guesswork.

Total IgG versus virus-specific IgG

Polyclonal hypergammaglobulinemia is a different test and a different problem. Zhao and colleagues (Lancet Haematology, 2021) organize causes into liver disease, autoimmunity/vasculitis, infection-inflammation, malignancy, hematologic disorders, IgG4-related disease, immunodeficiency syndromes, and iatrogenic Ig therapy. IL-6-high states with CRP persistently ≥30 mg/L are a common driver. Marked isolated IgG4 (>5 g/L) points toward IgG4-RD; mild IgG4 bumps are nonspecific.

Clinically: a patient with fatigue, high EBV VCA IgG, and normal total IgG is not the same patient as one with globulin 48 g/L, polyclonal gamma spike, high CRP, and abnormal ALT. The first needs a reactivation-versus-memory discussion. The second needs a systematic search for the driver of B-cell hyperactivity. Both can coexist.

Immunity: suppression, senescence, and inflammatory ignition

The 2026 IMPACC/Nature work is the most important recent correction to bedside dogma. In >1,150 hospitalized COVID-19 patients, nearly half had detectable transcripts from at least one chronic virus in the first 40 days. EBV tended to appear early; Anelloviridae persisted; HSV-1 and CMV rose later and were more respiratory. Among the severely ill, nasal/airway CMV or EBV tracked one-year mortality. Persistent Anelloviridae in convalescence associated with fatigue and physical disability. Steroid and immunosuppressant exposure did not explain herpesvirus reactivation. Systemic inflammation did.

That finding coexists with, rather than replaces, the older literature. CMV still inflates effector-memory and TEMRA pools and contributes to inflammaging. Combined high EBV and CMV titers associate with higher CRP and IL-6 in community-dwelling older adults. Multi-herpesvirus reviews through 2025–2026 describe cross-compartment priming: CMV-driven T-cell exhaustion can facilitate EBV reactivation and B-cell expansion; shared IL-6/TNF/NF-κB circuitry links the viruses to one another. Simultaneous CMV+EBV reactivation has independently predicted mortality in critical care (adjusted HR ~3.2 in synthesized ICU data).

Practical translation: do not wait for a transplant-level immunodeficiency before considering reactivation biology. Do not, however, equate every high titer with opportunistic infection. The intermediate phenotype — immunocompetent host, inflammatory illness, incomplete T-cell control, abortive lytic activity — is the one most relevant to outpatient chronic disease.

Disease-specific evidence, ranked by strength

1. Multiple sclerosis — high

Bjornevik et al., Science 2022: 10 million-person military cohort; 32-fold MS risk after EBV infection; no comparable CMV effect; sNfL rose only after EBV seroconversion. Complementary mechanistic work shows EBNA1–GlialCAM molecular mimicry. Anti-CD20 efficacy in MS is consistent with targeting the EBV B-cell reservoir, though that is not proof that antivirals would substitute for current disease-modifying therapy.

2. Acute COVID-19 severity and ICU reactivation — high for association, moderate for causality

Systematic reviews put EBV as the most frequent documented reactivating virus in COVID-19 cohorts, followed by HSV-1 and CMV. Simonnet and others reported ~85% herpesvirus reactivation in critically ill COVID-19, with EBV linked to longer stay. Multi-virus reactivation is common (one synthesis: 34–63%) and worse than single-virus detection. Whether treating CMV or HSV in selected ICU patients changes outcome remains context-specific and protocol-driven; indiscriminate outpatient antivirals do not follow from these data.

3. Long COVID / PASC — moderate, heterogeneous

Gold et al. (2021): EA-D IgG or VCA IgM in 66.7% of long-COVID subjects vs 10% of controls; EA-D correlated with symptom count. Peluso et al., JCI 2023: high EBNA IgG and EA-D independently associated with fatigue and neurologic long COVID after adjustment; CMV seropositivity unexpectedly associated with lower odds of neurocognitive long COVID. Karachaliou et al., J Med Virol 2024 (n=1,083): higher IgG to EBV EA-D, VZV, and WU polyomavirus in PASC, including non-severe index infections, at a median 31 months. 2026 Nature multi-omics: herpesvirus reactivation common acutely, but convalescent Anelloviridae — not EBV — was the cleaner PASC disability signal in that hospitalized cohort. Take-home: order a full EBV panel plus clinical judgment; do not promise that an EA-D result explains the entire syndrome.

4. ME/CFS — moderate association, no single-agent proof

Coxsackie, parvovirus B19, HHV-7, enterovirus, and herpesviruses have all been implicated in meta-analysis; effect sizes vary by detection method. 2025 sputum PCR work found higher EBV load in ME/CFS than controls. 2025–2026 dUTPase-IgG studies report multi-herpesvirus seroreactivity in a majority of ME/CFS patients versus a minority of controls, with antibody levels tracking fatigue. The abortive-lytic model (viral proteins produced without full virion output) is a coherent way to reconcile “PCR-negative blood, antibody-positive lytic antigens, high symptoms.” It is still a model.

5. Other autoimmunity — associative to mechanistic

SLE flares have been linked to VCA IgA and reactivation-compatible serology. RA, Sjögren’s, IBD, and type 1 diabetes show higher EBV seroprevalence, higher titers, and/or tissue viral proteins in multiple reviews. Causality is not uniform across diseases. MS remains the outlier in strength.

6. HBV reactivation — high, guideline-defined

Included because it is the template for how medicine already takes reactivation seriously. In HBsAg+ disease, reactivation is a DNA rise; in resolved infection (HBsAg−, anti-HBc+), it is reverse seroconversion or new DNAemia under immunosuppression. This is not analogical license to treat every high EBV IgG as if it were HBV under rituximab. It is proof that latent DNA viruses can cause preventable organ injury when surveillance drops.

A practical outpatient algorithm

Do not test EBV VCA IgG in isolation in a chronically fatigued adult and call the result diagnostic. If you test, order the panel: VCA IgM/IgG, EBNA-1 IgG, EA-D IgG. Add CMV IgG as context, not as a hunt for a second villain.
Interpret EA-D as “recent antigenic exposure possible,” not “treat now.” Repeat at 8–12 weeks if management would change. Consider PCR when there is fever, cytopenias, hepatitis, lymphadenopathy, suspected HLH, or immunosuppression.
Separate polyclonal IgG workup from virus-specific serology: SPEP, CRP, ALT/AST, quantitative immunoglobulins and subclasses if globulins are high, plus targeted autoimmune and infection tests.
Look for the second hit. Reactivation biology is more convincing when stacked with post-exertional malaise, new autonomic symptoms after an infection, documented lymphopenia or low NK function, or a clear inflammatory flare.
Treat terrain first in immunocompetent outpatients. Sleep, iron repletion, metabolic and gut inflammation, alcohol, overtraining, and uncontrolled autoimmunity change host control more reliably than nutraceutical “antivirals.” Evidence-based antivirals belong in defined disease (shingles, severe HSV, CMV syndromes, selected CAEBV/HLH pathways), not as a default for high IgG.
Refer rather than stretch labels. Extreme titers, cytopenias, rising ferritin/triglycerides, unexplained hepatitis, or progressive lymphadenopathy are hematology problems until proven otherwise.

What remains uncertain

Three gaps should stay on the page, not in the marketing copy. First, serologic reactivation markers are noisy; tissue-level lytic activity is hard to measure in clinic. Second, intervention trials that start with an EA-D-positive, immunocompetent, chronically fatigued adult and show that an antiviral or immune strategy changes validated outcomes are still thin. Third, Anelloviridae and other “commensal” chronic viruses may turn out to be better activity meters of immune failure than the herpesviruses we know how to name. Humility here is not nihilism. It is how this field stays scientific.

How we think about this at the clinic

At an integrative clinic the temptation is to treat every elevated viral IgG as a root cause. The opposite temptation, common in conventional settings, is to file the same result under “old infection, ignore.” Neither posture serves the person in the room.

A better frame is this. Latent viruses are part of the human immune landscape. When someone presents with post-infectious fatigue, new autoimmunity, recurrent mouth or skin herpes, unexplained inflammatory labs, or a long-COVID picture, viral reactivation is one of the mechanisms worth mapping — alongside gut ecology, metabolic strain, micronutrient status, hormones, sleep, and the obvious medical differentials. Mapping is not the same as declaring a single enemy. It is how you decide whether the next step is watchful waiting, a fuller panel, a referral, or a plan that lowers the inflammatory and metabolic load that lets latent viruses keep knocking.

This article is educational. It is not a diagnosis, a protocol, or a substitute for assessment by a qualified clinician who has examined the patient and the actual laboratory methods used.

Selected references

Bjornevik K, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296-301. doi:10.1126/science.abj8222
Gold JE, et al. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens. 2021;10(6):763.
Peluso MJ, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest. 2023;133(3):e163669.
Karachaliou M, et al. Antibody responses to common viruses according to COVID-19 severity and postacute sequelae of COVID-19. J Med Virol. 2024;96:e29862.
IMPACC / Nature 2026 cohort analyses and companion reporting: viral transcripts from herpesviruses and Anelloviridae in 1,154 hospitalized COVID-19 patients; inflammation-linked reactivation; convalescent Anelloviridae associated with PASC disability. Nature. 2026. See also CIDRAP and Science news summaries, August 2026.
Kim M, et al. Chronic viral reactivation and associated host immune response and clinical outcomes in acute COVID-19 and PASC. bioRxiv. 2024. doi:10.1101/2024.11.14.622799.
Rohrhofer J, et al. (and related 2025 sputum work). Higher EBV load in ME/CFS airway samples versus controls. Viruses. 2025;17(3):422.
Williams MV, et al. Chronic reactivation of persistent human herpesviruses EBV, HHV-6 and VZV and heightened anti-dUTPase IgG antibodies are a recurrent hallmark in post-infectious ME/CFS. J Med Virol. 2026;98(1).
Hwang J-H, et al. Evaluation of viral infection as an etiology of ME/CFS: a systematic review and meta-analysis. J Transl Med. 2023;21.
Zhao EJ, et al. Polyclonal hypergammaglobulinaemia: assessment, clinical interpretation, and management. Lancet Haematol. 2021;8(5):e365-e375.
Bennett JM, et al. Inflammation and reactivation of latent herpesviruses in older adults. Brain Behav Immun. 2012;26(2):337-345.
Solana R / Pawelec lineage and later reviews: CMV memory inflation, TEMRA expansion, and inflammaging. See Nikolich-Zugich J and subsequent systematic reviews of CMV and T-cell senescence.
De Paschale M, Clerici P. Serological diagnosis of Epstein-Barr virus infection: problems and solutions. World J Virol. 2012;1(1):31-43.
Kärjä V, et al. / CAEBV guidelines: Updated guidelines for chronic active Epstein–Barr virus disease. Int J Hematol. 2023.
Myint A, et al. Reactivation of hepatitis B virus: a review of clinical guidelines. Clin Liver Dis (Hoboken). 2020.
Lanz TV, et al. / Lanz–Robinson line of work on EBNA1–GlialCAM mimicry in MS. Nature / related 2022 mechanistic papers.
BMC Infect Dis systematic review. Viral reactivations and co-infections in COVID-19 patients. 2023;23.
Clinics and Practice / MDPI multi-herpesvirus inflammatory network reviews, 2025–2026, synthesizing ICU reactivation rates and CMV–EBV crosstalk.
Jones JF, et al. Antibodies to Epstein-Barr virus–specific DNase and DNA polymerase in the chronic fatigue syndrome. Arch Intern Med. 1988;148(9):1957-1960.

Dr. Jason Granzotto ND · Tri-Health Wellness Centre · Vaughan / Woodbridge, Ontario · trihealth.ca

Prepared as an educational briefing for clinic patients and referring clinicians. Laboratory methods and reference ranges vary; interpret results with the reporting laboratory’s assay and the patient’s full history. Not medical advice.

Downloads: Article downloads page · Clinic: Tri-Health Wellness Centre · Book: Jane booking